{
    "nctId": "NCT02473809",
    "officialTitle": "The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function",
    "inclusionCriteria": "* Informed consent\n* Diagnosis of type 2 diabetes (HbA1c \\> 48 mmol/mol)\n* Age older than 30 years\n* Must have minimum age of 30 Years\n* Must have maximum age of 90 Years",
    "exclusionCriteria": "* Type 1 diabetes\n* Treatment with insulin\n* Body weight \\> 140 kg\n* HbA1c \\> 75 mmol/mol\n* Treatment with GLP-1 analogues, Dipeptidyl peptidase-4 inhibitors, or glitazones\n* Chronic kidney disease\n* Hepatic disease\n* Pancreatitis\n* Inflammatory bowel disease\n* Osteoporosis\n* Family or personal history of medullary thyroid carcinoma\n* Treatment with glucocorticoids\n* Hormone replacement therapy\n* Diabetic gastroparesis\n* Pregnancy or lactation"
}